dna Communications

NEJM publishes bb2121 Phase 1 data in patients with multiple myeloma

The CRB-401 phase 1 study of bb2121, a BCMA-targeted CAR T-cell therapy, demonstrated manageable safety and deep and durable responses in heavily pre-treated patients. Treatment resulted in an 85% objective response rate with 73% achieving ≥ VGPR.

Sourcedna Communications·JournalNew England Journal of Medicine·DateMay 2, 2019

Phase III FIRST (MM-020/IFM 07-01) trial of REVLIMID (lenalidomide) plus dexamethasone in newly diagnosed multiple myeloma patients who are not candidates for stem cell transplant published in New England Journal of Medicine

A phase III trial found that continuous REVLIMID (lenalidomide) with dexamethasone improved progression-free survival and reduced risk of disease progression compared to standard treatment. Patients treated with continuous REVLIMID plus dexamethasone showed a significant reduction in risk of progression or death.

Sourcedna Communications·JournalNew England Journal of Medicine·DateSep 4, 2014